Regulation of insulin-like growth factor I receptor promoter activity by wild-type and mutant versions of the WT1 tumor suppressor

Endocrinology

Volumn 140, Issue 10, 1999, Pages 4713-4724

  Tajinda, K ^a   Carroll, J ^a   Roberts C T , Jr ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ARTICLE; DNA BINDING; EXON; GENE ACTIVITY; GENE CONTROL; GENE STRUCTURE; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; REGULATORY MECHANISM; TUMOR SUPPRESSOR GENE;

EID: 0033305238     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.140.10.7065     Document Type: Article

References (51)

1. Molecular and cellular aspects of the insulin-like growth factor I receptor
2. The role of the insulin-like growth factor system in human cancer
3. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation
4. The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis
5. Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250:1251, and 1316 in the carboxy-terminus of the IGF-I receptor
6. Essential role of tyrosine residues 1131, 1135, and 1136 of the insulin-like growth factor-I (IGF-I) receptor in IGF-I action
7. Blockade of the insulin-like growth-factor-I receptor inhibits growth of human colorectal cancer cells: Evidence of a functional IGF-II-mediated autocrine loop
8. Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: Autocrine growth stimulation by IGF-II Via the IGF-I receptor
9. Type 1 IGF receptor in human breast diseases
10. Growth regulation of human glioblastoma T98G cells by insulin-like growth factor-1 and its receptor
11. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor
12. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors
13. Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid
14. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms' tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms' tumor gene product
15. Transcriptional repression of the insulin-like growth factor I receptor (IGF-I-R) gene by the tumor suppressor WT1 involves binding to sequences both upstream and downstream of the IGF-I-R gene transcription start site
16. Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression
17. Insulin-like growth factors and Wilms' tumor
18. Decreased expression of the Wilm's tumor gene WT-1 and elevated expression of the IGF-II and the IGF-II and IGF-IR genes in prostatic stromal cells from patients with benign prostatic hyperplasia
19. Altered expression of the WT1 Wilms' tumor suppressor gene in human breast cancer
20. The Wilms' tumor 1 gene: Oncogene or tumor suppressor gene?
21. A second transcriptionally active DNA-binding site for the Wilms' tumor gene product, WT1
22. Regulation of insulin-like growth factor I receptor gene expression by Sp1: Physical and functional interactions of Sp1 at GC boxes and at a CT element
23. Alternative splicing and genomic structure of the Wims' tumor gene WT1
24. RNA editing in the Wilms' tumor susceptibility gene, WT1
25. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor
26. The role of WT1 in Wilms' tumorigenesis
27. A structure-function analysis of transcriptional repression mediated by the WT1 Wilms' tumor suppressor protein
28. Transcriptional repression mediated by the WT1 Wilms' tumor gene product
29. Structural and functional analysis of the insulin-like growth factor I receptor gene promoter
30. Identification of a new family of tissue-specific basic helix-loop-helix proteins with a two-hybrid system
31. An in vitro assay of β-galactosidase from yeast
32. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations
33. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome
34. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins
35. WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins
36. Truncated WT1 mutants alter the subnuclear localization of the wild-type protein
37. Antagonism of WT1 activity by protein self-association
38. Interaction mating reveals binary and ternary connections between Drosophilia cell cycle regulators
39. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, WT1
40. Repression of the transforming growth factor-β1 gene by the Wilms' tumor suppressor WT1 gene product
41. Products of alternatively spliced transcripts of the Wilms' tumor suppressor gene, WT1, have altered DNA binding specificity and regulate transcription in different ways
42. Repression of Pax-2 by WT1 during normal kidney development
43. The Wilms' tumor suppressor gene WT1 is negatively autoregulated
44. Modulation of DNA binding specificity by alternative splicing of the Wilms' tumor WT1 gene transcript
45. Regulation of nov by WT1: A potential role for nov in nephrogenesis
46. Identification of nuclear localization signals within the zinc fingers of the WT1 tumor suppressor gene product
47. The Wilms' tumor gene product, WT1, represses transcription of the platelet-derived growth factor A-chain gene
48. Repression of the insulin-like growth factor II gene by the Wilm's tumor suppressor WT1
49. Zinc fingers are sticking together
50. Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome
51. RNA binding by the Wilms' tumor suppressor zinc finger proteins